The Disappointment of the Biosimilar

Abstract

Get full access to this article

View all access options for this article.

References

Herber

, “The first drug with a $1 million price tag is already on the market,” Forbes, May 1, 2018, available at <https://www.forbes.com/sites/matthewherper/2012/05/01/the-first-drug-with-a-1-million-price-tag-is-already-on-the-market/#7bb318baabde> (last visited August 2, 2018).

Diependaele

et al ., “Similar or the Same? Why Biosimilars are not the Solution,” Journal of Law, Medicine & Ethics 46, no. 3 (2018): 776-790.

Beran ,

I. B.

Hirsch , and

J. S.

Yudkin , “Why are we Failing to Address the Issue of Access to Insulin? A National and Global Perspective,” Diabetes Care 41, no. 6 (2018): 1125-1131.

Heinemann

, “Biosimilar Insulins: How will this Story Evolve?” Diabetes Technology & Therapeutics 14 (2012):986-988.

J.A.

Greene

, Generic: The Unbranding of Modern Medicine (Baltimore: Johns Hopkins University Press, 2014).

A.B.

Engelberg

, “Special Patent Provisions for Pharmaceuticals: Have They Outlived Their Usefulness,” Specialty Law Digest: Health Care Law 258 (2000):9-48.